| Knowledge4COVID-19

Property	Value
is ?:annotates of	<https://research.tib.eu/covid-19/entity/34362602_HAS_TOPIC_C0003062> <https://research.tib.eu/covid-19/entity/34362602_HAS_TOPIC_C0010320> <https://research.tib.eu/covid-19/entity/34362602_HAS_TOPIC_C0010321> <https://research.tib.eu/covid-19/entity/34362602_HAS_TOPIC_C0011750> <https://research.tib.eu/covid-19/entity/34362602_HAS_TOPIC_C0018555> <https://research.tib.eu/covid-19/entity/34362602_HAS_TOPIC_C0018557> <https://research.tib.eu/covid-19/entity/34362602_HAS_TOPIC_C0018558> <https://research.tib.eu/covid-19/entity/34362602_HAS_TOPIC_C0020971> <https://research.tib.eu/covid-19/entity/34362602_HAS_TOPIC_C0042210> <https://research.tib.eu/covid-19/entity/34362602_HAS_TOPIC_C0086418> <https://research.tib.eu/covid-19/entity/34362602_HAS_TOPIC_C1567676> <https://research.tib.eu/covid-19/entity/34362602_HAS_TOPIC_C2713498> <https://research.tib.eu/covid-19/entity/34362602_HAS_TOPIC_C5203670> <https://research.tib.eu/covid-19/entity/34362602_HAS_TOPIC_C5203676> <https://research.tib.eu/covid-19/entity/34362602_HAS_TOPIC_C5387588> <https://research.tib.eu/covid-19/entity/34362602_HAS_TOPIC_C5392141>
?:authorAffiliation	[\'DCVMN International, Route de Crassier 7, 1262 Nyon, Switzerland. Electronic address: b.hayman@dcvmn.net.\', \'Quality Assist, Cape Town, South Africa.\']
?:citedBy	-1
?:creator	<https://research.tib.eu/covid-19/entity/Dennehy_Maureen> <https://research.tib.eu/covid-19/entity/Hayman_Benoit>
?:doi	S0264-410X(21)00922-110.1016/j.vaccine.2021.07.044
?:doi	<https://research.tib.eu/covid-19/entity/S0264-410X%2821%2900922-110.1016/j.vaccine.2021.07.044>
?:hasPublicationType	<https://research.tib.eu/covid-19/entity/Journal_Article>
?:journal	Vaccine
is ?:pmid of	<https://research.tib.eu/covid-19/entity/34362602>
?:pmid	<https://research.tib.eu/covid-19/entity/34362602>
?:pmid	34362602
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/Covid-19>
?:rankingScore_SJR	1.863
?:rankingScore_hIndex	159
?:title	Developing-country vaccine manufacturers\' technical capabilities can make a difference in global immunization.
?:type	<https://research.tib.eu/covid-19/vocab/Publication> <https://research.tib.eu/covid-19/vocab/Publication_Author>
?:year	2021

Metadata

Anon_0

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://purl.org/net/provenance/ns#DataItem>

<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>

<http://www.w3.org/2004/03/trix/rdfg-1/Graph>

<http://xmlns.com/foaf/0.1/primaryTopic>

<https://research.tib.eu/covid-19/entity/34362602>

<http://xmlns.com/foaf/0.1/topic>

Anon_0

<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes>

<https://research.tib.eu/covid-19/data/entity/34362602>

<http://purl.org/net/provenance/ns#createdBy>

Anon_1 (more)

expand all